MX2022014561A - Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19. - Google Patents

Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.

Info

Publication number
MX2022014561A
MX2022014561A MX2022014561A MX2022014561A MX2022014561A MX 2022014561 A MX2022014561 A MX 2022014561A MX 2022014561 A MX2022014561 A MX 2022014561A MX 2022014561 A MX2022014561 A MX 2022014561A MX 2022014561 A MX2022014561 A MX 2022014561A
Authority
MX
Mexico
Prior art keywords
treatment
covid
inhibitors
prevention
mek
Prior art date
Application number
MX2022014561A
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Michael Schindler
Helen Elisa Hoffmann
Julia Koch-Heier
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2022014561A publication Critical patent/MX2022014561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a inhibidores de MEK para uso en un método para el tratamiento de una infección por coronavirus y/o el tratamiento o prevención de la tormenta de citocinas de COVID-19. También se proporcionan composiciones que comprenden estos inhibidores para uso en el tratamiento de una infección por coronavirus, tal como COVID-19.
MX2022014561A 2020-05-20 2021-05-20 Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19. MX2022014561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20175739.0A EP3912623A1 (en) 2020-05-20 2020-05-20 Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (1)

Publication Number Publication Date
MX2022014561A true MX2022014561A (es) 2022-12-15

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014561A MX2022014561A (es) 2020-05-20 2021-05-20 Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.

Country Status (10)

Country Link
US (1) US20230241014A1 (es)
EP (2) EP3912623A1 (es)
JP (1) JP2023526836A (es)
KR (1) KR20230013077A (es)
CN (1) CN116635022A (es)
AU (1) AU2021277517A1 (es)
BR (1) BR112022023013A2 (es)
CA (1) CA3178137A1 (es)
MX (1) MX2022014561A (es)
WO (1) WO2021234097A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3697405T (lt) 2017-10-17 2021-10-25 Atriva Therapeutics Gmbh Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
WO2024073077A1 (en) * 2022-09-30 2024-04-04 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069960A2 (en) * 2001-03-06 2002-09-12 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock

Also Published As

Publication number Publication date
AU2021277517A1 (en) 2022-12-08
KR20230013077A (ko) 2023-01-26
WO2021234097A1 (en) 2021-11-25
CA3178137A1 (en) 2021-11-25
US20230241014A1 (en) 2023-08-03
JP2023526836A (ja) 2023-06-23
CN116635022A (zh) 2023-08-22
EP4153159A1 (en) 2023-03-29
BR112022023013A2 (pt) 2022-12-20
EP3912623A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
MX2022014561A (es) Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
WO2021158635A8 (en) Anti-viral compositions and methods of use
EP4143235A4 (en) METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
MX2022015601A (es) Compuesto para el tratamiento de infecciones coronavirales.
EP4093758A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS
MX2022010877A (es) Cepas bacterianas y composiciones de las mismas para uso oral en el tratamiento de infecciones virales del aparato respiratorio.
SG11202105728YA (en) Method and compositions for treating coronavirus infection
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
JOP20220138A1 (ar) طرق مُعالجة فيروس كورونا
MX2022003871A (es) Composiciones inmunogénicas.
WO2023122260A3 (en) Inhibitors of sars-cov-2
MX2023009041A (es) Uso de inhibidores del proteasoma en el tratamiento de infecciones por coronavirus.
EP4103192A4 (en) COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS
IL299751A (en) Preparations and methods for disinfection, treatment and prevention of bacterial infections
EP4153609A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING CORONAVIRUS INFECTION
WO2010128016A3 (en) Par2 agonists for use in the treatment or prevention of influenza virus type a infections
WO2022032112A3 (en) Compositions and methods for treating a coronavirus infection
EP4126031A4 (en) COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRUS INFECTIONS, INCLUDING CORONAVIRUS INFECTIONS, AND METHODS OF USE THEREOF
AU2021901169A0 (en) Novel compositions and methods for treating coronavirus infections
WO2022268916A3 (en) Pan-coronavirus peptide vaccine